Hot Features
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as ... NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.51 | -4.76491006627 | 31.69 | 33.42 | 29.61 | 1178414 | 31.70934071 | CS |
| 4 | -8.18 | -21.3242961418 | 38.36 | 38.87 | 29.61 | 1368147 | 33.96010912 | CS |
| 12 | -0.07 | -0.231404958678 | 30.25 | 42.205 | 27.85 | 1215840 | 33.61281794 | CS |
| 26 | -5.13 | -14.528462192 | 35.31 | 42.205 | 27.85 | 991917 | 33.5478167 | CS |
| 52 | 9.28 | 44.4019138756 | 20.9 | 42.205 | 17.63 | 1006973 | 31.33978857 | CS |
| 156 | 18.7 | 162.891986063 | 11.48 | 42.205 | 5.6326 | 608115 | 26.2449381 | CS |
| 260 | 19.18 | 174.363636364 | 11 | 42.205 | 5.6326 | 522212 | 26.04414707 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.